Rezafungin Acetate is a small molecule commercialized by Cidara Therapeutics, with a leading Pre-Registration program in Systemic Candidiasis. According to Globaldata, it is involved in 14 clinical trials, of which 11 were completed, 1 is ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Rezafungin Acetate’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Rezafungin Acetate is expected to reach an annual total of $366 mn by 2032 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Rezafungin Acetate Overview

Rezafungin acetate is under development for the treatment and prophylaxis of aspergillosis in COVID-19 patients, pneumocystis pneumonia,Trichophyton mentagrophytes, Trichophyton rubrum, Microsporum gypseum, systemic candida infections including candidemia and related cases of invasive candidiasis. The drug candidate is a long acting echinocandin. It is administered intravaginally, subcutaneously and intravenously as a solution and a gel. The drug candidate was under development for the treatment of vulvovaginal candidiasis.

Cidara Therapeutics Overview

Cidara Therapeutics (Cidara) formerly K2 Therapeutics is a biotechnology company. The company discovers, develops and commercializes novel anti-infectives including immunotherapies. Its pipeline products include rezafungin for the treatment of invasive fungal disease and CD388 for treating influenza. Cidara is investigating RSV AVC program for the treatment of respiratory syncytial virus (RSV), HIV AVC for human immunodeficiency viruses (HIV), CoV AVC for pan coronavirus. The company’s proprietary Cloudbreak, an antiviral platform for the fight against life-threatening infectious diseases that provides potent antiviral activity and immune system engagement in a single molecule. Cidara is headquartered in San Diego, California, the US.

The company reported revenues of (US Dollars) US$49.6 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$12.1 million in FY2020. The operating loss of the company was US$42.3 million in FY2021, compared to an operating loss of US$71.9 million in FY2020. The net loss of the company was US$42.5 million in FY2021, compared to a net loss of US$72.1 million in FY2020. The company reported revenues of US$40.7 million for the third quarter ended September 2022, compared to a revenue of US$13.3 million the previous quarter.

For a complete picture of Rezafungin Acetate’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.